[go: up one dir, main page]

EP1117820A1 - Fermentation of clavulanic acid at a controlled level of ammonia - Google Patents

Fermentation of clavulanic acid at a controlled level of ammonia

Info

Publication number
EP1117820A1
EP1117820A1 EP99947466A EP99947466A EP1117820A1 EP 1117820 A1 EP1117820 A1 EP 1117820A1 EP 99947466 A EP99947466 A EP 99947466A EP 99947466 A EP99947466 A EP 99947466A EP 1117820 A1 EP1117820 A1 EP 1117820A1
Authority
EP
European Patent Office
Prior art keywords
ammonium
clavulanic acid
concentration
fermentation
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99947466A
Other languages
German (de)
French (fr)
Inventor
Gesina Visser-Luirink
Wilhelmus Theodorus Antonius Maria De Laat
Jeroen Martijn Klop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM NV filed Critical DSM NV
Priority to EP99947466A priority Critical patent/EP1117820A1/en
Publication of EP1117820A1 publication Critical patent/EP1117820A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Definitions

  • the present invention relates to the field of the fermentative production of clavulanic acid by fermentation of a clavulanic acid producing microorganism.
  • Streptomycetes are known to produce a large variety of secondary metabolites which can be applied in the manufacturing of pharmaceuticals.
  • these pharmaceuticals belong to the classes produced by the Streptomycetes and are for instance polyketides, macrolides, anthracyclines, tetracyclins, lipopeptides and ⁇ -lactams, see further Strohl ( 1 997).
  • One particular example is the production of the ⁇ -lactamase inhibitor clavulanic acid, a ⁇ -lactam compound which is produced by various microbial strains belonging to the genus of Streptomycetes such as S. clavuligerus ATCC 27064, S. jumonjinensis (GB patent 1 5631 03), S. katsurahamanus IFO 1 371 6 FERM 3944 (JP patent 83009679B) and Streptomyces sp. P6621 FERM 2804 (JP patent application 551 62993A).
  • Such regulations may comprise the carbon catabolite, ammonium or phosphate repression or any other kind of metabolite that represses the synthesis of the secondary metabolite of interest.
  • Carbon catabolites and ammonium repress the production of cephalosporins in S. clavuligerus (Aharonowitz and Demain 1 978 and 1 979)
  • nitrogen catabolites regulate the production of spiramycin in S. ambofaciens (Untrau 1 994)
  • phosphate, ammonium and glutamate repress the production of clavulanic acid in S. clavuligerus (Romero et al. 1 984) .
  • Various types of regulations involved in cephamycin production with various Streptomycetes are described in Omstead et al ( 1 985). High ammonium concentrations were found to repress streptonigrin biosynthesis in S. flocculus (Wallace et al. 1 990).
  • a similar negative influence of ammonia on the cefaiosporin production by Streptomyces i. ⁇ o clavuligerus was already described by Aharonowitz and Demain ( 1 979) . Furthermore, as S.
  • clavuligerus is urease positive, which urease is repressed by NH 4 CI (see page 2478 of Bascaran et al ( 1 989)) and ureum has been produced during the clavulanic acid production (Elson, 1 993), the production of clavulanic acid by S. clavuligerus is described to be i. 15 especially high when the concentration of ammonium is kept low (WO 96/1 8743).
  • the concentration of ammonium is regulated by
  • the pH during this ⁇ o fermentation has been maintained between 6.5 and 7.5 and preferably the fermentation is carried out in a fed batch, continuous or semi-continuous mode.
  • the clavulanic acid production is largely improved compared to a fermentation process where the ammonium concentration is kept low ( ⁇ 50 mg/l).
  • nutrients can be fed to an industrial fermentor in order to provide the optimal physiological conditions with the i 25 aim to maximize output from a given fermentation process.
  • the residual ammonium concentration in a fermentation broth can be controlled at the desired concentration range by adding an ammonium source continuously or discontinously (intermittently) to the fermentor.
  • ammonium, ammonium salts like ammonium chloride, ammonium nitrate, ammonium phosphate and ammonium carbonate or urea as an ammonium precursor can be added as an alkaline titrant, eventually alternating with sodium hydroxide in order to prevent excess ammonium dosage.
  • the ammonium concentration can be reduced for instance by manipulation of the temperature or pH, which leads to an increased growth rate and an i. 5 increased ammonium consumption rate.
  • the ammonium concentration can be controlled by adjusting the flow of the nitrogen source or by manipulation of the alkaline titrant and/or the pH.
  • the ammonium concentration is maintained equal to or higher than 50 mg/l.
  • the i. ⁇ o ammonium concentration must be low enough for reducing the repression of secondary metabolism and avoiding toxicity of ammonium.
  • the ammonium concentration could be maintained below 2500 mg/l, preferably 1 000 mg/l, for instance 500 mg/l.
  • the microorganism used for production of clavulanic acid may be i. 15 any Streptomycete, optionally improved for growth and/or clavulanic acid production by means of classical strain improvement or by recombinant DNA techniques, for instance S. clavuligerus or S. jumonjinensis.
  • the production of clavulanic acid is carried out by fermentation of a Streptomycete on a suitable medium comprising various carbon and i. 20 energy sources like sugars such as glucose, fructose, sucrose, maltose, lactose, or polysaccharides like starch, maltodextrines and inuline or other fructose polymers, proteins such as flours from nuts, vegetables, seeds, cereals, grasses such as those useful in fermentation industry; soybean flour, lineseed flour, peanut flour, potato flour, sunflower, pea- or i.
  • sugars such as glucose, fructose, sucrose, maltose, lactose, or polysaccharides like starch, maltodextrines and inuline or other fructose polymers
  • proteins such as flours from nuts, vegetables, seeds, cereals, grasses such as those useful in fermentation industry
  • soybean flour, lineseed flour peanut flour, potato flour, sunflower, pea- or i.
  • nitrogen sources such as ammonium salts, ammonium, urea, nitrate, asparagine, aspartate, glutamate, lysine and from complex sources such as protein products derived from microbial source (yeast extract) or plants (corn steep liquor, soybean flour, cotton seed flour etc.) and animals (peptones) .
  • Phosphor is either supplied in the form of an inorganic salt, or as a phosphor protein like casein, or bound to inositol in the form of phytate as present in many plant protein sources like soybean flour or bound in nucleotides as present in yeast extracts.
  • inorganic anions such as sulphates, phosphates, chlorides, borates, molybdate, iodate and inorganic cations such as potassium, sodium, zinc, manganese, magnesium, iron, copper, cobalt, nickel may be added to the fermentation medium.
  • a fermentation is started by inoculating from a preculture or inoculum fermentation at a volume of 1 to 50% of the main fermentation medium, particularly from 5 to 20%.
  • the process may last from 24 to 400 hours and especially from 48 to 1 68 hours.
  • the temperature will be kept between 20 and 40 °C, in particular between 25 and 35 °C, and even more particular between 25 and 30 °C.
  • the pH should be maintained preferably at pH 6 to 8, more preferably between pH 6.5 and 7.5 by means of titration with an alkaline substance such as ammonia, sodium hydroxide, potassium hydroxide, calcium hydroxide, or an organic base like lysine, arginine and histidine or a combination of these alkaline substances and an acid substance, such as the inorganic acids like sulphuric acid, hydrochloric acid, phosphoric acid and nitric acid.
  • an organic acid may be used such as gl ⁇ tamate, citrate, gluconate or acetate.
  • the dissolved oxygen concentration is preferably controlled in the optimal range for the process by varying one or more of the following parameters: the oxygen concentration in the inlet gas, application of overpressure, modification of stirrer speed or airflow.
  • the range may vary between 0 and 1 00% of air saturation.
  • Carbon dioxide should be kept at non-toxic concentrations by increasing the airflow through the fermentor so that the carbon dioxide concentration in the outlet-gas is less than 5%, more particular less than 2.5%. i. 5
  • the fermentation can be carried out in a batch, a fed batch, or a continuous fermentation process mode.
  • the process may be carried out by controlling various non-growth limiting nutrients in their optimal concentrations.
  • these growth-non-limiting nutrients i. ⁇ o may contain any relevant source of carbon, nitrogen, phosphor or sulphur or may contain oxygen.
  • the recovery of the impure clavulanic acid solution as formed by the fermentative process of the present invention as well as the subsequent conversion thereof into a pharmaceutically acceptable salt i. 15 by methods known in the art do form an aspect of the present invention.
  • One of the most advantageous procedures is the conversion of the impure clavulanic acid into an amino salt thereof by adding the corresponding amino salt forming compound as for instance N,N,N',N'- tetramethylethylenediamine, 1 ,3-bis(di-methylamino)-2-propanol, t- i.
  • Streptomyces clavuligerus ATCC27064 was improved for clavulanic acid production by means of several rounds of classic mutation (UV, nitroso guanidine (NTG)) and selection in shake flask cultures i. 25 whereby clavulanic acid production was tested by imidazole methods as known in the art.
  • the strain was conserved as vegetative mycelium grown for 48 hours in Tryptone Soytone Broth-medium (TSB-medium) at 28 °C in a shaker incubator shaken at 280 rpm and stored frozen at -80 °C. i.
  • the inoculum fermentor After 72 hours of cultivation at 27 ° C, 1 00 ml of the culture is transferred to the inoculum fermentor with 70 I of steam-sterilized i. 5 medium at pH 7 containing glycerol (20-50 g/l), soybean flour (20-40 g/l), casein hydrolysate ( 1 0-50 g/l), mono potassium phosphate (2-5 g/l), a suitable trace element cocktail and synthetic antifoam ( 1 g/l).
  • the inoculum fermentation medium was again grown for 72 hours at 26-30 °C keeping the dissolved oxygen concentration above 25% of air i. ⁇ o saturation by increasing airflow, agitation and backpressure if required.
  • the main fermentation is inoculated by transferring 9 I of the inoculum broth to the main fermentor by pressurizing the inoculum fermentor containing 1 50 I medium sterilized by steam prior to inoculation.
  • the medium contained glycerol (50-100 g/l), soybean flour (5- i. 15 20 g/l), casein hydrolysate ( 1 0-50 g/l), mono potassium phosphate (0.5-2 g/l), a suitable trace element cocktail and synthetic antifoam (0.2 - 2 g/l).
  • the pH was maintained at 7 + /- 0.25 by titration with NaOH and sulphuric acid while the temperature was kept between 26 and 29 °C by pumping cooling water through the jackets of the fermentor.
  • the i. 20 dissolved oxygen concentration was kept above 25% of air saturation by increasing airflow, backpressure and stirrer speed if required.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism at a controlled level of at least 50 mg/l ammonia has been provided for. Under the application of these reaction conditions surprisingly high production levels of clavulanic acid have been obtained.

Description

Fermentation of clavulanic acid at a controlled level of ammonia
Field of the invention
The present invention relates to the field of the fermentative production of clavulanic acid by fermentation of a clavulanic acid producing microorganism.
Background of the invention
Streptomycetes are known to produce a large variety of secondary metabolites which can be applied in the manufacturing of pharmaceuticals. Examples of these pharmaceuticals belong to the classes produced by the Streptomycetes and are for instance polyketides, macrolides, anthracyclines, tetracyclins, lipopeptides and β-lactams, see further Strohl ( 1 997). One particular example is the production of the β-lactamase inhibitor clavulanic acid, a β-lactam compound which is produced by various microbial strains belonging to the genus of Streptomycetes such as S. clavuligerus ATCC 27064, S. jumonjinensis (GB patent 1 5631 03), S. katsurahamanus IFO 1 371 6 FERM 3944 (JP patent 83009679B) and Streptomyces sp. P6621 FERM 2804 (JP patent application 551 62993A).
Secondary metabolism is regulated in various ways in
Streptomycetes. Such regulations may comprise the carbon catabolite, ammonium or phosphate repression or any other kind of metabolite that represses the synthesis of the secondary metabolite of interest. Carbon catabolites and ammonium repress the production of cephalosporins in S. clavuligerus (Aharonowitz and Demain 1 978 and 1 979), nitrogen catabolites regulate the production of spiramycin in S. ambofaciens (Untrau 1 994), and phosphate, ammonium and glutamate repress the production of clavulanic acid in S. clavuligerus (Romero et al. 1 984) . The oxygen concentration influences the regulation of ammonium and phosphate on the antibiotic synthesis by S. clavuligerus (Fang & Demain, i. 5 1 995) . Various types of regulations involved in cephamycin production with various Streptomycetes are described in Omstead et al ( 1 985). High ammonium concentrations were found to repress streptonigrin biosynthesis in S. flocculus (Wallace et al. 1 990). A similar negative influence of ammonia on the cefaiosporin production by Streptomyces i. ιo clavuligerus was already described by Aharonowitz and Demain ( 1 979) . Furthermore, as S. clavuligerus is urease positive, which urease is repressed by NH4CI (see page 2478 of Bascaran et al ( 1 989)) and ureum has been produced during the clavulanic acid production (Elson, 1 993), the production of clavulanic acid by S. clavuligerus is described to be i. 15 especially high when the concentration of ammonium is kept low (WO 96/1 8743).
However, otherwise than described in the patent application WO 96/1 8743, surprisingly a large increase in the production of clavulanic acid with a Streptomycete was found when maintaining the ammonium i. 20 concentration in an optimal rather high concentration range of about minimal 50 mg/l. When this ammonium concentration range was applied, the production of clavulanic acid was improved by more than 20%.
The application of an ammonium concentration of at least 50 mg/l to obtain a surprisingly high yield of clavulanic acid has never been i. 25 described or suggested in the literature.
Summary of the invention
i. 30 A method has been provided for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism on a suitable medium comprising carbon and nitrogen sources wherein during the fermentation of the clavulanic acid producing mircoorganism the concentration of ammonia is maintained equal to or higher than 50 mg/l, particularly equal to or higher than 75 mg/l, more particularly equal to or higher than 1 00 mg/l. The concentration of ammonium is regulated by
5 applying one or two of the measures selected from regulation of the rate of ammonium addition, for instance ammonium sulfate or urea or regulation of the addition of one or more ammonium containing titrants selected from ammonia and ammonium hydroxide, combined for instance with sulfuric acid and sodium hydroxide. Preferably the pH during this ιo fermentation has been maintained between 6.5 and 7.5 and preferably the fermentation is carried out in a fed batch, continuous or semi-continuous mode.
i 15 Detailed description of the invention
According to the present invention it was surprisingly found that when the ammonium concentration is maintained equal to or higher than 50 mg/l, particularly equal to or higher than 75 mg/l and more particularly i. 20 equal to or higher than 1 00 mg/l, the clavulanic acid production is largely improved compared to a fermentation process where the ammonium concentration is kept low ( < 50 mg/l). By using fed batch fermentation techniques known in the art, nutrients can be fed to an industrial fermentor in order to provide the optimal physiological conditions with the i 25 aim to maximize output from a given fermentation process. As an example, the residual ammonium concentration in a fermentation broth can be controlled at the desired concentration range by adding an ammonium source continuously or discontinously (intermittently) to the fermentor. This can be done either directly by manipulating the flow of i. 30 the nitrogen source (ammonium, ammonium salts like ammonium chloride, ammonium nitrate, ammonium phosphate and ammonium carbonate or urea as an ammonium precursor), or indirectly by adding ammonium as an alkaline titrant, eventually alternating with sodium hydroxide in order to prevent excess ammonium dosage. Furthermore, the ammonium concentration can be reduced for instance by manipulation of the temperature or pH, which leads to an increased growth rate and an i. 5 increased ammonium consumption rate. The ammonium concentration can be controlled by adjusting the flow of the nitrogen source or by manipulation of the alkaline titrant and/or the pH.
According to the present invention the ammonium concentration is maintained equal to or higher than 50 mg/l. On the other hand, the i. ιo ammonium concentration must be low enough for reducing the repression of secondary metabolism and avoiding toxicity of ammonium. For instance, the ammonium concentration could be maintained below 2500 mg/l, preferably 1 000 mg/l, for instance 500 mg/l.
The microorganism used for production of clavulanic acid may be i. 15 any Streptomycete, optionally improved for growth and/or clavulanic acid production by means of classical strain improvement or by recombinant DNA techniques, for instance S. clavuligerus or S. jumonjinensis.
The production of clavulanic acid is carried out by fermentation of a Streptomycete on a suitable medium comprising various carbon and i. 20 energy sources like sugars such as glucose, fructose, sucrose, maltose, lactose, or polysaccharides like starch, maltodextrines and inuline or other fructose polymers, proteins such as flours from nuts, vegetables, seeds, cereals, grasses such as those useful in fermentation industry; soybean flour, lineseed flour, peanut flour, potato flour, sunflower, pea- or i. 25 beanflour, cotton seed flour, wheat gluten, whole wheat, rice meal, or proteins derived from animal sources called peptones, or proteins derived from microbial sources like yeast extracts, triglycerides such as soybean oil, sunflour oil, olive oil, tri-oleate etc., (poly-) alcohols such as ethanol, propanol, glycerol, mannitol, or organic acids or a salt thereof such as i. 30 acetate, propionate, succinate, adipate, malonate, fumarate, citrate, lactate, gluconate etc. and nitrogen sources such as ammonium salts, ammonium, urea, nitrate, asparagine, aspartate, glutamate, lysine and from complex sources such as protein products derived from microbial source (yeast extract) or plants (corn steep liquor, soybean flour, cotton seed flour etc.) and animals (peptones) . Phosphor is either supplied in the form of an inorganic salt, or as a phosphor protein like casein, or bound to inositol in the form of phytate as present in many plant protein sources like soybean flour or bound in nucleotides as present in yeast extracts.
Further vitamins and various sorts of inorganic anions such as sulphates, phosphates, chlorides, borates, molybdate, iodate and inorganic cations such as potassium, sodium, zinc, manganese, magnesium, iron, copper, cobalt, nickel may be added to the fermentation medium.
A fermentation is started by inoculating from a preculture or inoculum fermentation at a volume of 1 to 50% of the main fermentation medium, particularly from 5 to 20%. The process may last from 24 to 400 hours and especially from 48 to 1 68 hours. The temperature will be kept between 20 and 40 °C, in particular between 25 and 35 °C, and even more particular between 25 and 30 °C. The pH should be maintained preferably at pH 6 to 8, more preferably between pH 6.5 and 7.5 by means of titration with an alkaline substance such as ammonia, sodium hydroxide, potassium hydroxide, calcium hydroxide, or an organic base like lysine, arginine and histidine or a combination of these alkaline substances and an acid substance, such as the inorganic acids like sulphuric acid, hydrochloric acid, phosphoric acid and nitric acid. Alternatively, an organic acid may be used such as glαtamate, citrate, gluconate or acetate.
The dissolved oxygen concentration is preferably controlled in the optimal range for the process by varying one or more of the following parameters: the oxygen concentration in the inlet gas, application of overpressure, modification of stirrer speed or airflow. The range may vary between 0 and 1 00% of air saturation. Carbon dioxide should be kept at non-toxic concentrations by increasing the airflow through the fermentor so that the carbon dioxide concentration in the outlet-gas is less than 5%, more particular less than 2.5%. i. 5 The fermentation can be carried out in a batch, a fed batch, or a continuous fermentation process mode.
The process may be carried out by controlling various non-growth limiting nutrients in their optimal concentrations. Dependent on the growth limiting nutrient of choice, these growth-non-limiting nutrients i. ιo may contain any relevant source of carbon, nitrogen, phosphor or sulphur or may contain oxygen.
Of course, the recovery of the impure clavulanic acid solution as formed by the fermentative process of the present invention as well as the subsequent conversion thereof into a pharmaceutically acceptable salt i. 15 by methods known in the art do form an aspect of the present invention. One of the most advantageous procedures is the conversion of the impure clavulanic acid into an amino salt thereof by adding the corresponding amino salt forming compound as for instance N,N,N',N'- tetramethylethylenediamine, 1 ,3-bis(di-methylamino)-2-propanol, t- i. 20 butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethyl- amino)ethyl)ether and reacting said amine clavulanate with a non-toxic pharmaceutially acceptable salt as for instance potassium ethylhexanoate to form the corresponding purified salt, for instance potassium clavulanate. i. 25 The following examples are only to be considered as illustration of the present invention.
i. 30 References Strohl W.R., Biotechnology of Industrial Antibiotics, Marcel Dekker Inc., page 1-48 (1997).
Aharonowitz Y. and Demain A.L., Antimicrobial Agents and i 5 Chemotherapy Vol. 14, No.2, pages 159-164 (1978).
Aharonowitz Y. and Demain A.L., Can. J. Microbiol.25, 61-67 (1979).
Aharonowitz Y. and Friedrich C.G., Arch. Microbiol. 125, 137-142 i ιo (1980).
Elson S.W., Baggaley K.H., Davidson M., Fulston M., Nickolson N.H., Risbridger, G.D. and Tyler, J.W., J. Chem. Soc, Chem. Commun. 1213 (1993).
1 15
Butterworth, Biotechnology of Industrial Antibiotics, Marcel Dekker Inc., pages 225-235 (1984).
Romero J. Liras P. and Martin J.F., Appl. Microbiol. Biotechnol. 20, 318- i 20 325 (1984).
Omstead D.R., Hunt G.R. and Buckiand B.C. in Comprehensive Biotechnology Pergamon Press, Vol. 3, Edited by Harvey W. Blanch, Stephen Drew and Daniel I.C. Wang, pages 187-210 (1985).
25
Brana A.F., Paiva N. and Demain A.L., J. of Gen. Microbiol. 132, 1305- 1317 (1986).
Brana A.F., Wolfe S. and Demain A.L., Arch. Microbiol. 146, 46-51 so (1986). Bascaran V., Hardisson C. and Brana A.F., J. of General Microbiology 135, 2465-2474 (1989).
Bascaran V., Hardisson C. and Brana A.F., J. of General Microbiology i. 5 135, 2475-2482 (1989).
Wallace K.K., Payne G.F. and Speedie M.K., J. of Industrial Microbiology, 6, 43-48 (1990).
i. ιo Untrau S., Lebrihi A., Lefebvre G. and Germain P., Curr. Microbiol. 28 (1994).
Kasarenini S. and Demain A.L., J. of Industrial Microbiology 13, 217-219 (1994).
15
Fang A. and Demain A.L., J. of Industrial Microbiology 15, 407-410 (1995).
i 20 Example 1
Streptomyces clavuligerus ATCC27064 was improved for clavulanic acid production by means of several rounds of classic mutation (UV, nitroso guanidine (NTG)) and selection in shake flask cultures i. 25 whereby clavulanic acid production was tested by imidazole methods as known in the art. The strain was conserved as vegetative mycelium grown for 48 hours in Tryptone Soytone Broth-medium (TSB-medium) at 28 °C in a shaker incubator shaken at 280 rpm and stored frozen at -80 °C. i. 30 1 ml of the frozen mycelium was inoculated to 100 ml of a sterilized (30 minutes, 121 °C) preculture medium containing 5-20 g/l maltose.1aq, 15-30 g/l bacto tryptone, 15-30 g/l bacto peptone, 1-10 g/l bacto soytone, mono potassium phosphate ( 1 -5 g/l) and 0.2 g/l synthetic antifoam.
After 72 hours of cultivation at 27 ° C, 1 00 ml of the culture is transferred to the inoculum fermentor with 70 I of steam-sterilized i. 5 medium at pH 7 containing glycerol (20-50 g/l), soybean flour (20-40 g/l), casein hydrolysate ( 1 0-50 g/l), mono potassium phosphate (2-5 g/l), a suitable trace element cocktail and synthetic antifoam ( 1 g/l). The inoculum fermentation medium was again grown for 72 hours at 26-30 °C keeping the dissolved oxygen concentration above 25% of air i. ιo saturation by increasing airflow, agitation and backpressure if required.
The main fermentation is inoculated by transferring 9 I of the inoculum broth to the main fermentor by pressurizing the inoculum fermentor containing 1 50 I medium sterilized by steam prior to inoculation. The medium contained glycerol (50-100 g/l), soybean flour (5- i. 15 20 g/l), casein hydrolysate ( 1 0-50 g/l), mono potassium phosphate (0.5-2 g/l), a suitable trace element cocktail and synthetic antifoam (0.2 - 2 g/l).
The pH was maintained at 7 + /- 0.25 by titration with NaOH and sulphuric acid while the temperature was kept between 26 and 29 °C by pumping cooling water through the jackets of the fermentor. The i. 20 dissolved oxygen concentration was kept above 25% of air saturation by increasing airflow, backpressure and stirrer speed if required.
In case of ammonium controlled fermentations, 0.58 g/l of ammonium sulphate was added to the main fermentation medium after sterilisation and ammonium was fed to the fermentor using a sterile i. 25 diluted solution of the same containing 1 2 g/l NH3 as sulphate salt. The flow was adjusted to get the ammonium at the desired concentration range upon off-line measurement of the concentration of ammonium every 2 hours. When the concentration of ammonium in the broth got higher than 500 mg/l, the pH was increased by addition of an alkaline titrant i. 30 with 0.2 unit in order to reduce the ammonium concentration under that level. ln table 1 we see that when the ammonium concentration was controlled above 50 mg/l, the clavulanic acid production was increased with more than 25% in two independent runs. During the reference fermentation experiment ammonium has been below 50 mg/l for 35 hours; between 5 and 40 hours after inoculation. After this period ammonium rises due to clavulanic acid production.
Table 1 . Experimental results of clavulanic acid-fermentations on a 300 I scale with and without ammonium control.

Claims

1 . A method for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism on a suitable medium comprising carbon and nitrogen sources wherein during the fermentation of the clavulanic acid producing microorganism the concentration of ammonium is maintained about equal to or higher than 50 mg/l.
10
2. A method according to claim 1 , wherein the concentration of ammonium is maintained about equal to or higher 75 mg/l.
3. A method according to claim 2, wherein the concentration of i 15 ammonium is maintained about equal to or higher than on 1 00 mg/l.
4. A method according to anyone of the claims 1 , 2 or 3, wherein the concentration of ammonium is regulated by applying one or two of the measures selected from regulation of the rate of ammonium i 20 addition or regulation of the addition of one or more titrants.
5. A method according to claim 4, wherein the concentration of ammonium is regulated by the addition of ammonium sulfate or urea.
i 25 6. A method according to claim 4, wherein the concentration of ammonium is regulated by the addition of one or more titrants selected from ammonia and ammonium hydroxide, combined with sulfuric acid and optionally sodium hydroxide.
i 30 7. A method according to anyone of the claims 1 - 6, characterized by maintaining the pH between 6.5 and 7.5.
8. A method according to anyone of the claims 1 - 7 wherein the fermentation is carried out in a fed batch, continuous or semi- continuous mode.
i. 5 9. A method for the purification of clavulanic acid wherein impure clavulanic acid from the fermentation broth produced according to anyone of the claims 1 - 8 is isolated and purified subsequently.
1 0. A method according to claim 9, and subsequent conversion i. ιo to a non-toxic pharmaceutically acceptable salt thereof by converting the impure clavulanic acid into an amine salt thereof by adding the corresponding amine salt forming compound and reacting said amine clavulanate with a non-toxic pharmaceutically acceptable salt to form the corresponding purified salt of clavulanic acid.
I. 15
EP99947466A 1998-09-29 1999-09-23 Fermentation of clavulanic acid at a controlled level of ammonia Withdrawn EP1117820A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99947466A EP1117820A1 (en) 1998-09-29 1999-09-23 Fermentation of clavulanic acid at a controlled level of ammonia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98203314 1998-09-29
EP98203314 1998-09-29
EP99947466A EP1117820A1 (en) 1998-09-29 1999-09-23 Fermentation of clavulanic acid at a controlled level of ammonia
PCT/EP1999/007390 WO2000018947A1 (en) 1998-09-29 1999-09-23 Fermentation of clavulanic acid at a controlled level of ammonia

Publications (1)

Publication Number Publication Date
EP1117820A1 true EP1117820A1 (en) 2001-07-25

Family

ID=8234177

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99947466A Withdrawn EP1117820A1 (en) 1998-09-29 1999-09-23 Fermentation of clavulanic acid at a controlled level of ammonia

Country Status (6)

Country Link
EP (1) EP1117820A1 (en)
CN (1) CN1198940C (en)
AU (1) AU6089699A (en)
CA (1) CA2342181A1 (en)
TR (1) TR200100873T2 (en)
WO (1) WO2000018947A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933717A (en) * 2007-04-27 2013-02-13 科学与工业研究委员会 Process for preparation of clavulanic acid employing streptomyces clavuligerus mtcc 1142 in solid state fermentation
RU2628696C1 (en) * 2013-10-02 2017-08-21 Адзиномото Ко., Инк. A method for producing basic amino acid (variants)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026044B1 (en) * 1979-08-24 1983-06-08 Beecham Group Plc Amine salt of clavulanic acid, its preparation and use
GB9424950D0 (en) * 1994-12-10 1995-02-08 Smithkline Beecham Plc Novel process
SI9600120A (en) * 1996-04-12 1997-12-31 Lek Tovarna Farmacevtskih New and improved fermentative procedure for the production of clavulanic acid and its salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0018947A1 *

Also Published As

Publication number Publication date
WO2000018947A1 (en) 2000-04-06
CN1198940C (en) 2005-04-27
AU6089699A (en) 2000-04-17
TR200100873T2 (en) 2001-07-23
CN1320166A (en) 2001-10-31
CA2342181A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
KR20000075487A (en) Fermentative production of valuable compounds on an industrial scale using chemically defined media
AU762656B2 (en) Method of producing gamma-decalactone
JP3313730B2 (en) Method for producing clavulanic acid and / or its salt
US6440708B1 (en) Fermentation of clavulanic acid at a controlled level of ammonia
WO2000018947A1 (en) Fermentation of clavulanic acid at a controlled level of ammonia
CA2336363A1 (en) Fermentation process to produce clavulanic acid at a low concentration of free amino acids
JP2004180672A (en) Microorganism which produces riboflavin and method for producing the riboflavin by using the same
AU2005254730B2 (en) Fermentation process using faba beans as nitrogen source
US20080318289A1 (en) Fermentation Processes for the Preparation of Tacrolimus
MXPA01002858A (en) Fermentation of clavulanic acid at a controlled level ofammonia
EP2287324A2 (en) Fermentation processes with low concentrations of carbon- and nitrogen-containing nutrients
RU2835689C1 (en) Method of producing riboflavin
SI9600120A (en) New and improved fermentative procedure for the production of clavulanic acid and its salts
CA1119981A (en) Process for preparing 2,5-diketogluconic acid
JPH05244973A (en) Actinomasura fibrosa species nov. Method for producing polyether antibiotics from NRRL 18348 and Actinomystine sp. NRRL 18880
US6500651B1 (en) Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid
SU553283A1 (en) Alcohol dehydrogenase production method
KR0169061B1 (en) A process for preparing xylitol by controlling fermenting condition
JPWO2003031638A1 (en) Method for producing D-alanine
JPH0523748B2 (en)
Leonhartsberger et al. Use of collagen hydrolysate as a complex nitrogen source for the synthesis of penicillin by Penicillium chrysogenum
HU185652B (en) Process for producing riboflavine with microbiological method
KR880002418B1 (en) Method of producing inosine and guanosine
JPH04252189A (en) Production of benzenedicarboxlic monoester or derivative thereof
JPH04234995A (en) Production of d-pantolactone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010226;LT PAYMENT 20010226;LV PAYMENT 20010226;MK PAYMENT 20010226;RO PAYMENT 20010226;SI PAYMENT 20010226

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DSM IP ASSETS B.V.

17Q First examination report despatched

Effective date: 20031007

RTI1 Title (correction)

Free format text: FERMENTATION OF CLAVULANIC ACID AT A CONTROLLED CONCENTRATION OF AMMONIUM

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003